Catherine E. Scull

Catherine E. Scull

Auto-generated profile, based on publicly available information

Catherine E. Scull

Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in Trends in Genetics
Verified
Journal Article
Closed access
CSCatherine E. Scull
Catherine E. Scull
DSDavid Schneider
David Schneider

1 June 2018 in Biophysical Journal
Verified
Journal Article
Closed access
FAFrancis D. Appling
Francis D. Appling
CSCatherine E. Scull
Catherine E. Scull
ALAaron L. Lucius
Aaron L. Lucius
DSDavid Schneider
David Schneider

9 August 2019 in Biochemical Journal
Verified
Journal Article
Closed access
PDF file
CSCatherine E. Scull
Catherine E. Scull
YZYinfeng Zhang
Yinfeng Zhang
NTNichole Tower
Nichole Tower
LRLynn Rasmussen
Lynn Rasmussen
IPIndira Padmalayam
Indira Padmalayam
DSDavid Schneider
David Schneider
Over the past two decades, ribosome biogenesis has emerged as an attractive target for cancer treatment. In this study, two high-throughput screens were used to identify ribosome biogenesis inhibitors. Our primary screen made use of the HaloTag selective labeling strategy to identify compounds that decreased the abundance of newly synthesized ribosomes in A375 malignant melanoma cells. This screen identified 5786 hit compounds. A subset of those initial hit compounds were tested using a secondary screen that directly measured pre-ribosomal RNA (pre-rRNA) abundance as a reporter of rRNA synthesis rate, using quantitative RT-PCR. From the secondary screen, we identified two structurally related compounds that are potent inhibitors of rRNA synthesis. These two compounds, Ribosome Biogenesis Inhibitors 1 and 2 (RBI1 and RBI2), induce a substantial decrease in the viability of A375 cells, comparable to the previously published ribosome biogenesis inhibitor CX-5461. Anchorage-independent cell growth assays further confirmed that RBI2 inhibits cell growth and proliferation. Thus, the RBI compounds have promising properties for further development as potential cancer chemotherapeutics.

16 December 2019 in Journal of Biological Chemistry
Verified
Journal Article
Closed access
PDF file
CSCatherine E. Scull
Catherine E. Scull
ACAndrew M. Clarke
Andrew M. Clarke
ALAaron L. Lucius
Aaron L. Lucius
DSDavid Schneider
David Schneider